On November 8, 2024, Sarah London, CEO of Centene Corp (CNC, Financial), purchased 4,117 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 667,229 shares of Centene Corp.
Centene Corp, a prominent healthcare company, offers a portfolio of services to government-sponsored healthcare programs, focusing on under-insured and uninsured individuals. The company operates in a crucial segment of the healthcare industry, providing a spectrum of health solutions through a wide network of local health plans.
The transaction occurred with the stock priced at $60.8 per share, valuing the purchase at approximately $250,509.60. This acquisition has contributed to a total of 4,117 shares bought by the insider over the past year, with no shares sold during the same period.
Insider transaction trends at Centene Corp over the last year show a total of 1 insider buy and 4 insider sells. The recent purchase by the CEO suggests a noteworthy move, considering the broader insider selling trend.
Centene Corp's shares are currently trading with a market cap of approximately $30.37 billion. The stock's price-earnings ratio stands at 10.44, which is lower than both the industry median of 21.32 and the company’s historical median.
According to the GF Value, the intrinsic value of the stock is estimated at $84.46, indicating that at the current price of $60.8, Centene Corp is modestly undervalued with a price-to-GF-Value ratio of 0.72.
This insider buying activity could be a signal to investors, especially in the context of the stock’s valuation and recent price trends. Investors and analysts often monitor insider buys as they can indicate executives' confidence in the company's future performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
